1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment.
2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease.
Evidence Rating Level: 2 (Good)
Study Rundown: Crohn’s...